A Phase 2 interventional study of Lurbinectedin in Advanced Solid Tumor, Metastatic Solid Tumor and Urothelial Cancer, sponsored by Jazz Pharmaceuticals. Terminated at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-28.
Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,054 studies in Neoplasm Metastasis with a site in United States — 346 open to participants now, 542 under way, 58 of them phase 3. Neoplasm Metastasis · United States.
Among the 2,054 studies in Neoplasm Metastasis with a site in United States, this one is the 873rd largest by enrollment of the 1,863 interventional ones that give a count, is one of 106 that started in 2022, is one of 566 in phase 2, and was the 1,620th registered.
4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.
Browse Neoplasm Metastasis studies →346 of the 2,054 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
SystImmune Inc. · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
LTZ Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,054 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 976 · Phase 2 855 · Phase 3 186 · Phase 4 15
First in 1978; this study’s year is marked. 106 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is close to the median of 50 across 3,271 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 43 across the 1,863 interventional studies, 100 across the 139 observational. Of the 1,391 that completed or were terminated, 602 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
925 of 2,054 have an industry lead sponsor. The 10 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Jazz Pharmaceuticals has 4 studies filed under Neoplasm Metastasis — fewer than ten, so there is no comparison to draw.
203 of the studies in Neoplasm Metastasis with a site in United States that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03525873Phase 3M.D. Anderson Cancer CenterA Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy | 2026-12-31 |
| NCT03927885Phase 3M.D. Anderson Cancer CenterOpen Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer | 2026-12-31 |
| NCT06947928Phase 3TuHURA Biosciences, Inc.Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma | 2027-03-31 |
| NCT06506955Phase 3Taiho Oncology, Inc.Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. | 2027-04 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
Add all 203 to your calendar (.ics) → With an account.
Among the 2,054 studies in Neoplasm Metastasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicenter, phase 2 study of lurbinectedin monotherapy in participants with advanced (metastatic and/or unresectable) solid tumors.
This phase 2, multicenter, open-label study is designed to assess the safety and efficacy of lurbinectedin monotherapy in 3 cohorts of participants with high-unmet medical need: advanced (metastatic and/or unresectable) urothelial cancer (UC), poorly differentiated neuroendocrine carcinomas (PD-NEC), and a homologous recombination deficient-positive malignancies agnostic cohort.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have advanced (/unresectable) cancers in one of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with advanced (metastatic and/or unresectable) urothelial carcinoma who have progressed on platinum-containing regimen (prior therapies may include but are not limited to immune checkpoint inhibitor, enformumab vendotin, or sacituzumab govitecan) will receive Lurbinectedin 3.2 mg/m\^2 intravenous (IV) on Day 1 of every 3 weeks (Q3W) cycle until confirmed disease progression, withdrawal of participant consent, participant lost to follow-up, unacceptable toxicity, or the study or individual cohort may be terminated by the sponsor for lack of efficacy signal or any other reason.
Drug: Lurbinectedin
Participants with advanced (metastatic and/or unresectable) poorly differentiated neuroendocrine carcinomas who received at least 1 prior line of therapy will receive Lurbinectedin 3.2 mg/m\^2 intravenous (IV) on Day 1 of every 3 weeks (Q3W) cycle until confirmed disease progression, withdrawal of participant consent, participant lost to follow-up, unacceptable toxicity, or the study or individual cohort may be terminated by the sponsor for lack of efficacy signal or any other reason.
Drug: Lurbinectedin
Participants with advanced (metastatic and/or unresectable) endometrial, biliary tract, urothelial, breast (TNBC or HR+HER2- breast cancer), pancreas, gastric, or esophageal solid tumors with preidentified germline and/or somatic pathogenic mutation and received at least 1 prior line of therapy will receive Lurbinectedin 3.2 mg/m\^2 intravenous (IV) on Day 1 of every 3 weeks (Q3W) cycle until confirmed disease progression, withdrawal of participant consent, participant lost to follow-up, unacceptable toxicity, or the study or individual cohort may be terminated by the sponsor for lack of efficacy signal or any other reason.
Drug: Lurbinectedin
Lurbinectedin 3.2 mg/m\^2 intravenous (IV) every 3 weeks (Q3W)
Investigator-Assessed Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1
The ORR is defined as the proportion of participants whose best overall response (BOR) is investigator-assessed confirmed complete response (CR) or partial response (PR) using the RECIST v1.1 criteria. BOR is defined as the best response recorded between the date of first dose and the date of objectively documented progression per RECIST v1.1, or the date of subsequent anticancer therapy, death due to any cause, loss to follow-up, or study discontinuation, whichever occurs first.
Time frame: Baseline to disease progression or death, up to 36 weeks.
Investigator-Assessed Progression Free Survival (PFS) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1
PFS is defined as the time from the first dosing date to the date of first documented disease progression or death due to any cause, whichever occurs first.
Time frame: Baseline to disease progression or death, up to 36 weeks
Investigator-Assessed Time-To-Response (TTR) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1
TTR is defined as the time from the first dosing date to the date of the first confirmed response (complete response \[CR\] or partial response \[PR\]), as assessed by the investigators.
Time frame: Baseline to disease progression or death, up to 36 weeks
Investigator-Assessed Duration of Response (DOR) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1
DOR is defined as the time from the first confirmed response (complete response \[CR\] or partial response \[PR\]) to the date of the first documented tumor progression as determined using RECIST v1.1 criteria or death due to any cause, whichever occurs first
Time frame: Baseline to disease progression or death, up to 36 weeks
Investigator-assessed Disease Control Rate (DCR) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1
DCR is defined as the proportion of participants whose best overall response (BOR) is confirmed complete response (CR), or partial response (PR), or stable disease (SD) using the RECIST v1.1 criteria.
Time frame: Baseline to disease progression or death, up to 36 weeks.
Overall Survival (OS) in Participants Treated With Lurbinectedin
OS is defined as the time from the first dosing date to the date of death from any cause. A participant who has not died will be censored at the last known alive date
Time frame: Baseline and every 3 months, up to 16 months
A total of 47 participants who met all eligibility criteria were enrolled and received treatment were included
| Milestone | Urothelial Cancer (UC) Cohort | Poorly Differentiated Neuroendocrine Carcinomas (PD-NEC) Cohort | Homologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort |
|---|---|---|---|
| Started | 15 | 12 | 20 |
| Completed | 0 | 0 | 0 |
| Not completed | 15 | 12 | 20 |
| Withdrew: Withdrawal by subject | 3 | 0 | 4 |
| Withdrew: Death | 9 | 3 | 5 |
| Withdrew: Study terminated by sponsor | 0 | 1 | 2 |
| Withdrew: Progressive disease | 1 | 4 | 3 |
| Withdrew: Sponsor decision- no further os follow up required | 2 | 4 | 6 |
The ORR is defined as the proportion of participants whose best overall response (BOR) is investigator-assessed confirmed complete response (CR) or partial response (PR) using the RECIST v1.1 criteria. BOR is defined as the best response recorded between the date of first dose and the date of objectively documented progression per RECIST v1.1, or the date of subsequent anticancer therapy, death due to any cause, loss to follow-up, or study discontinuation, whichever occurs first.
| Participants | Urothelial Cancer (UC) Cohort | Poorly Differentiated Neuroendocrine Carcinomas (PD-NEC) Cohort | Homologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort |
|---|---|---|---|
| Investigator-Assessed Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 | 0 | 2 | 1 |
PFS is defined as the time from the first dosing date to the date of first documented disease progression or death due to any cause, whichever occurs first.
| months | Urothelial Cancer (UC) Cohort | Poorly Differentiated Neuroendocrine Carcinomas (PD-NEC) Cohort | Homologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort |
|---|---|---|---|
| Investigator-Assessed Progression Free Survival (PFS) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 | 1.46 (0.89 to 3.32) | 2.07 (1.18 to 2.89) | 1.38 (1.35 to 2.79) |
TTR is defined as the time from the first dosing date to the date of the first confirmed response (complete response \[CR\] or partial response \[PR\]), as assessed by the investigators.
| months | Urothelial Cancer (UC) Cohort | Poorly Differentiated Neuroendocrine Carcinomas (PD-NEC) Cohort | Homologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort |
|---|---|---|---|
| Investigator-Assessed Time-To-Response (TTR) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 | — | 2.76 (2.7 to 2.8) | 1.31 |
DOR is defined as the time from the first confirmed response (complete response \[CR\] or partial response \[PR\]) to the date of the first documented tumor progression as determined using RECIST v1.1 criteria or death due to any cause, whichever occurs first
| months | Urothelial Cancer (UC) Cohort | Poorly Differentiated Neuroendocrine Carcinomas (PD-NEC) Cohort | Homologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort |
|---|---|---|---|
| Investigator-Assessed Duration of Response (DOR) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 | — | 5.67 (2.8 to 8.6) | 2.79 |
DCR is defined as the proportion of participants whose best overall response (BOR) is confirmed complete response (CR), or partial response (PR), or stable disease (SD) using the RECIST v1.1 criteria.
| Participants | Urothelial Cancer (UC) Cohort | Poorly Differentiated Neuroendocrine Carcinomas (PD-NEC) Cohort | Homologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort |
|---|---|---|---|
| Investigator-assessed Disease Control Rate (DCR) as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 | 4 | 5 | 7 |
OS is defined as the time from the first dosing date to the date of death from any cause. A participant who has not died will be censored at the last known alive date
| months | Urothelial Cancer (UC) Cohort | Poorly Differentiated Neuroendocrine Carcinomas (PD-NEC) Cohort | Homologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort |
|---|---|---|---|
| Overall Survival (OS) in Participants Treated With Lurbinectedin | 4.99 (0.92 to 14.52) | NA (2.66 to NA) | NA (2.89 to NA) |
Collected over Adverse events were collected from the start of dosing of study drug up until 30 days after last study dose, up to approximately 10 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Urothelial Cancer (UC) Cohort | 9/15 (60%) | 9/15 (60%) | 15/15 (100%) |
| Poorly Differentiated Neuroendocrine Carcinomas (PD-NEC) Cohort | 3/12 (25%) | 3/12 (25%) | 12/12 (100%) |
| Homologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort | 5/20 (25%) | 8/20 (40%) | 19/20 (95%) |
| Event | Urothelial Cancer (UC) Cohort | Poorly Differentiated Neuroendocrine Carcinomas (PD-NEC) Cohort | Homologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort |
|---|---|---|---|
| FatigueGeneral disorders | 0/15 | 0/12 | 2/20 |
| Neutrophil count decreasedInvestigations | 1/15 | 0/12 | 2/20 |
| Acute kidney injuryRenal and urinary disorders | 0/15 | 0/12 | 2/20 |
| Cardiac ArrestCardiac disorders | 0/15 | 1/12 | 0/20 |
| Mouth haemorrhageGastrointestinal disorders | 0/15 | 1/12 | 0/20 |
| PneumoniaInfections and infestations | 0/15 | 1/12 | 0/20 |
| Cerebrovascular accidentNervous system disorders | 0/15 | 1/12 | 0/20 |
| NauseaGastrointestinal disorders | 1/15 | 0/12 | 0/20 |
| VomitingGastrointestinal disorders | 1/15 | 0/12 | 0/20 |
| Chest painGeneral disorders | 1/15 | 0/12 | 0/20 |
| Event | Urothelial Cancer (UC) Cohort | Poorly Differentiated Neuroendocrine Carcinomas (PD-NEC) Cohort | Homologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 9/15 | 2/12 | 2/20 |
| ConstipationGastrointestinal disorders | 2/15 | 6/12 | 4/20 |
| NauseaGastrointestinal disorders | 4/15 | 6/12 | 9/20 |
| FatigueGeneral disorders | 6/15 | 6/12 | 8/20 |
| Platelet count decreasedInvestigations | 7/15 | 1/12 | 6/20 |
| Neutrophil count decreasedInvestigations | 6/15 | 1/12 | 3/20 |
| VomitingGastrointestinal disorders | 4/15 | 2/12 | 7/20 |
| DiarrhoeaGastrointestinal disorders | 2/15 | 4/12 | 3/20 |
| Alanine aminotransferase increasedInvestigations | 3/15 | 4/12 | 5/20 |
| Blood alkaline phosphatase increasedInvestigations | 5/15 | 4/12 | 2/20 |
The baseline demographic characteristics were assessed in the Safety Analysis Set.
| Age, Categorical(Participants) | Urothelial Cancer (UC) Cohort | Poorly Differentiated Neuroendocrine Carcinomas (PD-NEC) Cohort | Homologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 5 | 11 | 23 |
| >=65 years | 8 | 7 | 9 | 24 |
| Sex: Female, Male(Participants) | Urothelial Cancer (UC) Cohort | Poorly Differentiated Neuroendocrine Carcinomas (PD-NEC) Cohort | Homologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort | Total |
|---|---|---|---|---|
| Female | 1 | 5 | 12 | 18 |
| Male | 14 | 7 | 8 | 29 |
| Ethnicity (NIH/OMB)(Participants) | Urothelial Cancer (UC) Cohort | Poorly Differentiated Neuroendocrine Carcinomas (PD-NEC) Cohort | Homologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 1 | 3 |
| Not Hispanic or Latino | 15 | 9 | 18 | 42 |
| Unknown or Not Reported | 0 | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Urothelial Cancer (UC) Cohort | Poorly Differentiated Neuroendocrine Carcinomas (PD-NEC) Cohort | Homologous Recombination Deficient-Positive Malignancies Agnostic (HRD) Cohort | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 1 | 4 |
| White | 11 | 8 | 17 | 36 |
| More than one race | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 1 | 1 | 2 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — In accordance with ICMJE requirements, Jazz Pharmaceuticals may provide qualified external researchers access to individual participant data (IPD) and clinical trial data that underlie the results of this trial upon request. Qualified researchers can submit a request on https://www.jazzpharma.com/science/clinical-trial-data-sharing/ as outlined. Jazz Pharmaceuticals reserves the right not to consider a request. For inquiries about Jazz's data sharing policy contact clinicaldatasharing@jazzpharma.com.
Data sharing details ↗ · www.jazzpharma.com
Ran from Mar 2022 to primary completion in Dec 2023, 21 months.
Results were first posted in Feb 2025, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PM 01183